Conflitti Paolo, Lyman Edward, Sansom Mark S P, Hildebrand Peter W, Gutiérrez-de-Terán Hugo, Carloni Paolo, Ansell T Bertie, Yuan Shuguang, Barth Patrick, Robinson Anne S, Tate Christopher G, Gloriam David, Grzesiek Stephan, Eddy Matthew T, Prosser Scott, Limongelli Vittorio
Euler Institute, Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Lugano, Switzerland.
Department of Physics and Astronomy, University of Delaware, Newark, DE, USA.
Nat Rev Drug Discov. 2025 Apr;24(4):251-275. doi: 10.1038/s41573-024-01083-3. Epub 2025 Jan 2.
G protein-coupled receptors (GPCRs) are the largest human membrane protein family that transduce extracellular signals into cellular responses. They are major pharmacological targets, with approximately 26% of marketed drugs targeting GPCRs, primarily at their orthosteric binding site. Despite their prominence, predicting the pharmacological effects of novel GPCR-targeting drugs remains challenging due to the complex functional dynamics of these receptors. Recent advances in X-ray crystallography, cryo-electron microscopy, spectroscopic techniques and molecular simulations have enhanced our understanding of receptor conformational dynamics and ligand interactions with GPCRs. These developments have revealed novel ligand-binding modes, mechanisms of action and druggable pockets. In this Review, we highlight such aspects for recently discovered small-molecule drugs and drug candidates targeting GPCRs, focusing on three categories: allosteric modulators, biased ligands, and bivalent and bitopic compounds. Although studies so far have largely been retrospective, integrating structural data on ligand-induced receptor functional dynamics into the drug discovery pipeline has the potential to guide the identification of drug candidates with specific abilities to modulate GPCR interactions with intracellular effector proteins such as G proteins and β-arrestins, enabling more tailored selectivity and efficacy profiles.
G蛋白偶联受体(GPCRs)是人类最大的膜蛋白家族,可将细胞外信号转化为细胞反应。它们是主要的药理学靶点,约26%的上市药物以GPCRs为靶点,主要作用于其正构结合位点。尽管它们很重要,但由于这些受体复杂的功能动力学,预测新型GPCR靶向药物的药理作用仍然具有挑战性。X射线晶体学、冷冻电子显微镜、光谱技术和分子模拟方面的最新进展加深了我们对受体构象动力学以及配体与GPCRs相互作用的理解。这些进展揭示了新的配体结合模式、作用机制和可成药口袋。在本综述中,我们重点介绍针对GPCRs的最近发现的小分子药物和候选药物的这些方面,重点关注三类:变构调节剂、偏向配体以及二价和双位点化合物。尽管目前的研究大多是回顾性的,但将配体诱导的受体功能动力学的结构数据整合到药物发现流程中,有可能指导鉴定具有特定能力的候选药物,以调节GPCR与细胞内效应蛋白(如G蛋白和β-抑制蛋白)的相互作用,从而实现更具针对性的选择性和疗效。